The increasing prevalence of patients who require frequent hospital admissions is fostering growth of the Europe Viscosupplementation market
The
Europe Viscosupplementation market segments include single dose, delayed onset
of action (DAA) capsules, sustained-release capsules, and multiple-dose vial
products. Based on therapeutic product type, the European market is further
divided into single injection, three-dose, and five-dose capsules. Single-dose
capsules are recommended to be used as an immediate relief for allergic
rhinitis and may provide significant clinical improvement, while three or
five-dose capsules are recommended for patients with mild to moderate chronic
rhinitis and provide significant clinical improvement. For patients who have
moderate to severe persistent sinusitis it is not recommended due to the slow
elimination phase associated with the product and prolonged release of
medications in the body.
The
increasing prevalence of patients who require frequent hospital admissions and
long periods of operative management can be expected to result in a dramatic
increase in the Europe
Viscosupplementation market over the forecast period. The growing
popularity of the single-dose regime can be attributed to the ease of
administration, consistent delivery system, and adequate pain relief. The
single-dose capsules are usually manufactured in single batches and delivered
to the patients in accordance with the manufacturing instructions. The three
and five-dose capsules can be manufactured in volume quantities and are often
shipped in refrigerated conditions for longer shelf life. Single-dose and three
and five-dose options are currently being marketed across Europe.
Eastern
and Western Europe viscosupplementation market sectors are expected to
experience strong growth in the coming years, driven primarily by the
increasing number of new patients. In addition, the aging population in Eastern
Europe is contributing to the high level of health-related costs. As per the
recent trends in the pharmaceutical industry, the demand for safe and effective
drugs is increasing in Europe. The availability of the single-dose capsule is
another factor that has played a key role in encouraging more patients to adopt
this drug as an alternative treatment option.
Comments
Post a Comment